X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3926) 3926
Publication (683) 683
Patent (104) 104
Book Chapter (31) 31
Book / eBook (14) 14
Web Resource (8) 8
Book Review (5) 5
Magazine Article (3) 3
Newspaper Article (3) 3
Conference Proceeding (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1669) 1669
middle aged (1018) 1018
oncology (993) 993
index medicus (964) 964
adult (916) 916
aged (914) 914
male (914) 914
female (911) 911
hematology (864) 864
treatment outcome (518) 518
aged, 80 and over (517) 517
article (457) 457
prognosis (457) 457
antineoplastic agents - therapeutic use (372) 372
leukemia (365) 365
adolescent (362) 362
cancer (347) 347
chronic myelogenous leukemia (342) 342
abridged index medicus (309) 309
imatinib mesylate (307) 307
therapy (306) 306
antineoplastic combined chemotherapy protocols - therapeutic use (299) 299
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (296) 296
hematology, oncology and palliative medicine (255) 255
remission induction (255) 255
hemic and lymphatic diseases (238) 238
benzamides (236) 236
leukemia, myeloid, acute - drug therapy (235) 235
research (233) 233
acute myeloid-leukemia (228) 228
young adult (227) 227
care and treatment (225) 225
chronic myeloid leukemia (225) 225
survival analysis (222) 222
chemotherapy (221) 221
survival (218) 218
pyrimidines - therapeutic use (214) 214
chronic myeloid-leukemia (210) 210
mutation (199) 199
acute myeloid leukemia (195) 195
survival rate (195) 195
protein kinase inhibitors - therapeutic use (193) 193
disease-free survival (181) 181
piperazines - therapeutic use (181) 181
follow-up studies (175) 175
acute myelogenous leukemia (165) 165
imatinib (162) 162
dasatinib (161) 161
acute lymphoblastic-leukemia (153) 153
myelodysplastic syndromes (150) 150
retrospective studies (150) 150
leukemia, myelogenous, chronic, bcr-abl positive - genetics (149) 149
drug therapy (147) 147
drug administration schedule (146) 146
antineoplastic agents - adverse effects (144) 144
philadelphia chromosome (140) 140
risk factors (140) 140
myelodysplastic syndromes - drug therapy (139) 139
cytarabine - administration & dosage (138) 138
myelodysplastic syndrome (134) 134
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (133) 133
protein-tyrosine kinases - antagonists & inhibitors (130) 130
leukemia, myeloid, acute - genetics (127) 127
recurrence (125) 125
antineoplastic combined chemotherapy protocols - adverse effects (123) 123
antineoplastic agents - administration & dosage (121) 121
aml (116) 116
leukemia, myeloid, acute - mortality (116) 116
dose-response relationship, drug (114) 114
analysis (111) 111
pyrimidines - administration & dosage (109) 109
drug resistance, neoplasm (106) 106
bcr-abl (105) 105
cytarabine (105) 105
interferon-alpha (103) 103
patients (103) 103
fusion proteins, bcr-abl - genetics (102) 102
minimal residual disease (102) 102
time factors (100) 100
patient outcomes (99) 99
cells (98) 98
leukemia, myelogenous, chronic, bcr-abl positive - pathology (96) 96
acute lymphoblastic leukemia (95) 95
transplantation (94) 94
tyrosine kinase inhibitor (94) 94
diagnosis (93) 93
pyrimidines - adverse effects (93) 93
acute disease (92) 92
cml (92) 92
expression (92) 92
genetic aspects (92) 92
salvage therapy (92) 92
clinical trials as topic (91) 91
disease progression (90) 90
health aspects (87) 87
mutations (87) 87
dosage and administration (86) 86
leukemia, myelogenous, chronic, bcr-abl positive - mortality (86) 86
neoplasms (86) 86
cytogenetics (85) 85
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (6) 6
Online Resources - Online (5) 5
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (4) 4
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
Online (2) 2
St. Michael's Hospital - Online (2) 2
Sunnybrook Health Sciences Centre - Online (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Credit Valley Hospital - Online (1) 1
Robarts - Stacks (1) 1
Scarborough Hospital - General (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4085) 4085
French (40) 40
German (16) 16
Chinese (7) 7
Korean (4) 4
Spanish (2) 2
Hungarian (1) 1
Japanese (1) 1
Norwegian (1) 1
Polish (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


New England Journal of Medicine, ISSN 0028-4793, 10/2010, Volume 363, Issue 17, pp. 1674 - 1675
Journal Article
2008, Hematologic malignancies, ISBN 3540723021, x, 294
Better therapy of acute leukemias depends ultimately on better understanding of the distinction between leukemic and normal progenitor cells. Thus, several... 
Acute leukemia -- Treatment | Acute leukemia | Clinical & internal medicine
Book
1998, Seminars in hematology, Volume 35, no. 3., 38
Book
Leukemia, ISSN 0887-6924, 2012, Volume 26, Issue 9, pp. 2061 - 2068
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 612 - 621
Journal Article
American Journal of Hematology, ISSN 0361-8609, 05/2014, Volume 89, Issue 5, pp. 547 - 556
Journal Article
2004, Hematology/oncology clinics of North America, Volume 18, no. 3., xvi p., p. [525]-782
Book
The New England Journal of Medicine, ISSN 0028-4793, 06/2018, Volume 378, Issue 25, pp. 2386 - 2398
Among patients with IDH1 -mutated relapsed or refractory leukemia, daily oral ivosidenib, an IDH1 inhibitor, induced molecular clearance of leukemic cells from... 
MEDICINE, GENERAL & INTERNAL | IDH2 MUTATIONS | METAANALYSIS | ACUTE MYELOID-LEUKEMIA | PROGNOSTIC-SIGNIFICANCE | DIFFERENTIATION | INHIBITOR | Glycine - analogs & derivatives | Recurrence | Follow-Up Studies | Glycine - adverse effects | Cell Count | Humans | Middle Aged | Pyridines - pharmacokinetics | Drug Resistance, Neoplasm | Male | Isocitrate Dehydrogenase - antagonists & inhibitors | Dose-Response Relationship, Drug | Enzyme Inhibitors - administration & dosage | Young Adult | Pyridines - adverse effects | Enzyme Inhibitors - pharmacokinetics | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Glycine - administration & dosage | Enzyme Inhibitors - adverse effects | Glycine - pharmacokinetics | Pyridines - administration & dosage | Administration, Oral | Isocitrate Dehydrogenase - genetics | Survival Rate | Remission Induction | Leukemia, Myeloid, Acute - mortality | Adolescent | Aged | Mutation | Hemoglobins - analysis | Leukemia, Myeloid, Acute - genetics | Usage | Myelocytic leukemia | Gene mutations | Physiological aspects | Genetic aspects | Nonlymphoid leukemia | Research | Drug therapy | Isocitrate dehydrogenase | Risk factors | Thrombocytopenia | Myeloid leukemia | Leukemia | FDA approval | Cancer therapies | Patients | Investigations | Leukocytosis | Collaboration | Point mutation | Remission | Acute myeloid leukemia | Drug dosages | Neutropenia | Tumors
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2017, Volume 376, Issue 10, pp. 917 - 927
Journal Article